GLK-411

GLK-411 is a preclinical-stage therapeutic candidate being developed by Glaukos for the treatment of diabetic macular edema (DME). It consists of a next-generation chemical entity (NCE) conjugate delivered via a bio-erodible sustained-release platform. The drug is administered through an intravitreal injection and is designed to provide long-term therapeutic effects while minimizing the frequency of injections required for patients with retinal vascular diseases. While the specific molecular target and mechanism of action of the NCE have not been publicly disclosed, the program leverages Glaukos' expertise in sustained-release ophthalmic drug delivery systems to improve treatment outcomes and patient compliance in DME.